Vitiligo [2026]: Causes, Autoimmune Triggers, and Prescription Treatment Options

Last updated: October 29, 2026 Reviewed by PrescribedGlow Editorial Team, Editorial

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. Our editorial opinions are our own.

Vitiligo is a chronic autoimmune skin disorder in which cytotoxic T-lymphocytes selectively destroy pigment-producing melanocytes, resulting in smooth, chalk-white patches of complete depigmentation on the face, hands, and body. While not contagious or medically dangerous, vitiligo is treatable: FDA-approved ruxolitinib 1.5% cream (Opzelura), topical calcineurin inhibitors, corticosteroids, and narrowband UVB phototherapy can halt immune destruction and stimulate follicular repigmentation.

Affiliate Disclosure: PrescribedGlow is supported by our readers. When you purchase prescription treatments through links on our site, we may earn an affiliate commission at no extra cost to you.

What causes vitiligo and what triggers a flare-up?

Vitiligo develops when autoreactive CD8+ cytotoxic T cells infiltrate the basal layer of the epidermis and release interferon-gamma (IFN-$\gamma$). This cytokine activates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in surrounding keratinocytes, prompting them to secrete chemokines (CXCL9 and CXCL10) that recruit additional T cells to destroy melanocytes.

According to a population-based cross-sectional study of over 40,000 adults by Gandhi et al. in JAMA Dermatology (2022, PMID: 34787670), the overall point prevalence of vitiligo among U.S. adults is 0.76% to 1.11% (approximately 1.9 million to 2.8 million adults), with roughly 40% of cases remaining undiagnosed.

In genetically predisposed individuals, new patches or rapid flare-ups are commonly precipitated by:

  • The Koebner Phenomenon: Mechanical skin trauma—such as cuts, scrapes, friction, laser treatments, or severe sunburns—releases oxidative stress signals (damage-associated molecular patterns) that trigger new depigmented patches along the exact site of injury.
  • Chemical Phenols: Repeated skin contact with phenolic compounds found in permanent hair dyes, rubber adhesives, or certain industrial synthetics mimics tyrosine and induces melanocyte oxidative stress.
  • Autoimmune Comorbidities: Around 15% to 25% of vitiligo patients have a co-existing autoimmune condition, most frequently Hashimoto’s thyroiditis, Graves’ disease, alopecia areata, or psoriasis.

How do you tell vitiligo apart from tinea versicolor or hypopigmentation?

Vitiligo presents as sharply demarcated, smooth, non-scaly macules and patches of complete melanin absence (depigmentation), most commonly distributed symmetrically around the eyes, mouth, fingers, wrists, and body folds. In contrast, fungal infections and post-inflammatory marks cause partial pigment lightening (hypopigmentation) with indistinct borders or surface scaling.

Per Karray and McKinney in StatPearls (PMID: 29494106) and Leung et al. in Dermatology and Therapy (2022, PMID: 36452877), tinea versicolor is a superficial Malassezia yeast overgrowth affecting 1.1% of populations in temperate climates and up to 50% in tropical regions, where fungal azelaic acid temporarily inhibits tyrosinase on the chest and back. Meanwhile, eczema (atopic dermatitis) and psoriasis flares can leave behind temporary post-inflammatory hypopigmentation—the lighter counterpart to post-inflammatory hyperpigmentation—once plaques resolve.

Clinical Feature Vitiligo Tinea Versicolor Post-Inflammatory Hypopigmentation
Primary Mechanism Autoimmune CD8+ T-cell melanocyte loss Malassezia yeast tyrosinase inhibition Impaired melanin transfer post-rash
Pigment Loss Complete depigmentation (chalk-white) Partial hypopigmentation (fawn/pink/tan) Partial hypopigmentation
Surface Texture Completely smooth; non-scaly Fine, powdery superficial scale Smooth or matches healing rash
Typical Location Face, periorificial, hands, wrists, folds Sebum-rich chest, upper back, shoulders Exact footprint of prior eczema or injury

Can vitiligo go away on its own or be reversed?

Yes, vitiligo pigment loss is biologically reversible in most anatomic regions, though complete spontaneous resolution is rare. While the autoimmune T-cell attack wipes out mature melanocytes in the interfollicular epidermis, unpigmented melanocyte stem cells residing inside the immune-privileged hair follicle bulge usually survive unless the hair itself turns white (leukotrichia).

In a clinical cross-sectional study of 167 vitiligo patients published in the Indian Journal of Dermatology, Venereology and Leprology (2020, PMID: 31793491), 21.5% of patients experienced partial spontaneous repigmentation after at least three months off therapy (frequently triggered by ambient sun exposure), but only 3.6% achieved complete spontaneous repigmentation.

Because repigmentation relies on hair follicle reservoirs, facial and neck lesions—which have a dense concentration of vellus hair follicles—repigment fastest, typically showing tiny “perifollicular” islands of color that expand and merge. Conversely, glabrous (hairless) skin on the fingertips, lips, wrists, and ankles lacks follicular melanocyte reservoirs and responds much more slowly to therapy.

What are the best prescription treatments for vitiligo?

Modern vitiligo management combines targeted topical immunomodulators—to silence the IFN-$\gamma$ and T-cell attack—with ultraviolet light stimulation to awaken dormant follicular melanocytes. Treatment selection depends on affected body surface area (BSA) and anatomical sensitivity.

1. FDA-Approved Topical JAK Inhibitor: Opzelura (Ruxolitinib 1.5% Cream)

Approved by the FDA in July 2022 for nonsegmental vitiligo affecting up to 10% BSA in patients aged 12 and older, Opzelura (ruxolitinib 1.5% cream) is the first prescription medication specifically cleared for vitiligo repigmentation. By selectively inhibiting JAK1 and JAK2 enzymes at the skin level, it blocks IFN-$\gamma$ signaling so melanocytes can regenerate.

In the landmark Phase 3 TRuE-V1 and TRuE-V2 trials published by Rosmarin et al. in The New England Journal of Medicine (2022, PMID: 36260792), 29.8% and 30.9% of patients applying ruxolitinib 1.5% cream twice daily achieved at least 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) at Week 24, compared to 7.4% and 11.4% on vehicle cream. With continuous use through Week 52, 50.3% of patients achieved F-VASI75.

2. Topical Calcineurin Inhibitors (Tacrolimus & Pimecrolimus) and Corticosteroids

Before and alongside JAK inhibitors, dermatologists rely on off-label steroid-sparing tacrolimus 0.1% ointment (Protopic) and pimecrolimus 1% cream (Elidel) for thin facial, eyelid, and neck skin, while using potent topical corticosteroids (like mometasone furoate 0.1% or clobetasol propionate 0.05%) on thicker body skin.

According to a systematic review and meta-analysis of 46 studies (1,499 patients) by Lee et al. in JAMA Dermatology (2019, PMID: 31141108), topical calcineurin inhibitor monotherapy achieved at least mild repigmentation ($\ge$25%) in 55.0% of all patients and 73.1% of face and neck lesions (with 35.4% achieving $\ge$75% marked facial repigmentation) without causing steroid-induced skin atrophy. When combined with phototherapy, $\ge$25% repigmentation rose to 89.5% (and 47.5% marked $\ge$75% response).

3. Narrowband UVB (NB-UVB) Phototherapy

For generalized vitiligo or synergy with topicals, targeted excimer laser (308 nm) or full-body narrowband UVB (311 nm) phototherapy stimulates melanocyte migration. A meta-analysis of 35 prospective studies (1,428 patients) by Bae et al. in JAMA Dermatology (2017, PMID: 28355423) demonstrated that NB-UVB achieved at least mild ($\ge$25%) repigmentation in 74.2% of patients at 6 months and marked ($\ge$75%) repigmentation in 35.7% at 12 months, peaking at 44.2% marked response on the face and neck.

Can you get prescription vitiligo treatment online?

Yes, patients with localized or facial vitiligo can access clinical evaluations and prescription topicals online. While in-office Wood’s lamp exams and cabinet NB-UVB phototherapy require a physical clinic, online medical dermatology platforms can review photographs of well-demarcated depigmented patches and prescribe topical calcineurin inhibitors, corticosteroids, or Opzelura cream to your local pharmacy.

Understanding how telehealth works helps distinguish cosmetic compounding brands from medical teledermatology clinics:

  • Honeydew Care: Operates as a full-service virtual dermatology clinic across all 50 states ($39/month billed monthly with a 3-month minimum, $32/month on a 4-month plan, or $299/year). Licensed dermatology providers evaluate pigment disorders via photo or video, send prescriptions for tacrolimus 0.1% ointment, topical corticosteroids, or Opzelura (ruxolitinib 1.5% cream) to your local pharmacy, and manage insurance prior authorizations so commercial insurance, Medicare, or Medicaid covers eligible medications (Honeydew Care). Read our full Honeydew Care review.
  • Nurx: Provides asynchronous dermatology consultations for chronic skin rashes and pigment concerns, routing FDA-approved generic topical corticosteroids and calcineurin inhibitors to your pharmacy with commercial insurance coordination (Nurx). See our Nurx review.
  • Cosmetic Compounding Note: Popular D2C dark-spot platforms like Musely, Agency, and Dermatica specialize in hyperpigmentation (such as melasma) using hydroquinone and kojic acid to bleach excess pigment. They do not treat vitiligo repigmentation, as tyrosinase inhibitors will further depigment skin.

Frequently asked questions

What causes vitiligo and what triggers a flare-up? Vitiligo is an autoimmune disorder in which autoreactive CD8+ cytotoxic T cells selectively destroy melanin-producing melanocytes in the epidermis via interferon-gamma (IFN-$\gamma$) and JAK-STAT signaling. Flare-ups and new patches are commonly triggered by physical skin trauma (the Koebner phenomenon), severe sunburns, chemical phenols, emotional stress, or comorbid autoimmune thyroid disease.

How do you tell vitiligo apart from tinea versicolor or hypopigmentation? Vitiligo causes smooth, non-scaly, chalk-white patches of complete pigment loss (depigmentation) with sharp borders, often arranged symmetrically around the face, hands, and body folds. Tinea versicolor causes slightly scaly, partially lightened macules on the oily upper trunk from Malassezia yeast, while post-inflammatory hypopigmentation follows the footprint of a prior rash.

Can vitiligo go away on its own or be reversed? While vitiligo rarely resolves completely on its own, pigment loss is biologically reversible if melanocyte stem cells in the hair follicle bulge remain intact. Clinical studies show that roughly 21.5% of patients experience partial spontaneous repigmentation off treatment, while targeted prescription topicals and phototherapy actively stimulate follicular melanocytes to repopulate the skin.

What is the best prescription treatment for vitiligo? Opzelura (ruxolitinib 1.5% cream) is the first FDA-approved topical JAK inhibitor specifically indicated for nonsegmental vitiligo repigmentation. Dermatologists also prescribe off-label topical calcineurin inhibitors like tacrolimus 0.1% ointment for sensitive facial skin, potent topical corticosteroids for body patches, and narrowband UVB (NB-UVB) phototherapy for widespread disease.

How long does Opzelura (ruxolitinib cream) take to work for vitiligo? Because melanocyte precursors must multiply inside hair follicles and migrate outward to the epidermis, repigmentation is gradual. In Phase 3 TRuE-V clinical trials, approximately 30% of patients achieved at least 75% facial repigmentation (F-VASI75) by Week 24, rising to 50.3% after 52 weeks of twice-daily application.

Can you get prescription vitiligo treatment online? Yes, online medical dermatology clinics like Honeydew Care and Nurx evaluate vitiligo asynchronously via high-resolution skin photos. Licensed dermatology providers can prescribe steroid-sparing topical tacrolimus ointment, pimecrolimus cream, topical corticosteroids, or FDA-approved Opzelura cream—and handle insurance prior authorizations—routed directly to your local pharmacy.

Bottom line

Vitiligo is a chronic autoimmune condition, not a cosmetic flaw, and repigmentation is achievable when active T-cell inflammation is halted early. Whether you opt for FDA-approved Opzelura (ruxolitinib 1.5% cream) or steroid-sparing tacrolimus 0.1% ointment alongside daily broad-spectrum SPF 50+ protection, virtual medical dermatology clinics make accessing specialist prescriptions and prior authorizations straightforward from home.

Consult a Dermatology Provider at Honeydew Care → · Explore Online Dermatology at Nurx →

Explore related condition hubs on alopecia areata autoimmune hair loss, psoriasis causes and non-steroidal treatments, eczema (atopic dermatitis) barrier care, and post-inflammatory hyperpigmentation.


Sources: PMID 34787670 · PMID 36260792 · PMID 31141108 · PMID 28355423 · PMID 31793491 · PMID 29494106 · PMID 36452877